Cancer Patients Reshape Clinical Trials With Their Stories

Twenty-year-old Jacob Knudsen has joined multiple clinical trials for his bone cancer, but each decision required his family to spend months researching options across the country. His experience shows what researchers are finally understanding: the best medical trials are designed with patients, not just for them.

Jacob's challenge is becoming less common thanks to organizations bringing patients directly into the research process. MIB Agents, founded to improve outcomes for osteosarcoma patients, now connects young people living with this rare bone cancer directly with the scientists designing their treatments.

The shift is producing real results. When one cancer trial at MD Anderson failed to enroll enough patients, researchers used feedback from patient interviews to redesign the study. The second attempt succeeded.

Dr. Eugenie Kleinerman from MD Anderson says the patient insights "changed the trial design and provided the rationale that we needed." What researchers discovered was simple: patients weren't avoiding trials because they feared experimental treatment, but because the logistics made participation nearly impossible.

Travel emerged as one of the biggest barriers. Many trials operate at single hospitals, forcing families to fly across the country repeatedly while managing the costs themselves. Jacob knows this reality well, having traveled extensively for his own treatment.

Communication gaps also keep patients from enrolling. Jacob wishes he could learn how treatments are performing for other participants, not for guarantees but for context. Patients understand uncertainty, but they need enough information to make decisions that fit their lives.

The patient advocacy approach gained momentum after two teenagers on MIB Agents' Junior Advisory Board presented at an FDA meeting about their trial experiences. One young woman joined from her living room because she was too sick to travel. She died two weeks later.

Why This Inspires

Her testimony helped pass the Mikayla Naylon Give Kids a Chance Act, named in her honor and signed into law shortly after her death. Young patients facing life-threatening illness are now shaping the laws that govern their own care.

MIB Agents created OsteoBites, a webinar series where lead researchers explain their trials directly to patients and families, then answer questions in real time. This transparency goes far beyond typical trial listings that use complex medical language.

The organization's Research Bee initiative gathers patient insights through interviews and focus groups, then delivers those findings to scientists before trials launch. Clinical research coordinators who participate report clearer communication and greater trust from patients.

Speed matters too. For patients with relapsed disease, waiting years for results isn't academic but life-altering. The research community is learning that patient timelines must shape scientific ones, not the other way around.

Jacob's advice to others considering trials reflects this new partnership: "You really have to do your research." Thanks to patient advocates, that research is finally becoming something families can actually do.